EMA to streamline bioequivalence testing for specific generic substances
This article was originally published in SRA
Executive Summary
Companies planning generic drug submissions in the EU are to have new guidance on how to demonstrate the bioequivalence of specific active substances, in an effort to make bioequivalence assessment more transparent and predictable.